


# Faraday Discussions

Accepted Manuscript



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

This article can be cited before page numbers have been issued, to do this please use: M. Gantz, S. V. Mathis, F. Nintzel, P. Lio and F. Hollfelder, *Faraday Discuss.*, 2024, DOI: 10.1039/D4FD00065J.

# On synergy between ultrahigh throughput screening and machine learning in biocatalyst engineering

View Article Online  
DOI: 10.1039/D4FD00065J

Maximilian Gantz<sup>1#</sup>, Simon V. Mathis<sup>2#</sup>, Friederike E. H. Nintzel<sup>1#</sup>,  
Pietro Lio<sup>2</sup> & Florian Hollfelder<sup>1\*</sup>

#Equal contribution.

<sup>1</sup>Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, CB2 1GA, UK

<sup>2</sup>Department of Computer Science, University of Cambridge, 15 JJ Thomson Avenue Cambridge CB3 0FD, UK

## Abstract

Protein design and directed evolution have separately contributed enormously to protein engineering. Without being mutually exclusive, the former relies on computation from first principles, while the latter is a combinatorial approach based on chance. Advances in ultrahigh throughput (uHT) screening, next generation sequencing and machine learning may create alternative routes to engineered proteins, where functional information linked to specific sequences is interpreted and extrapolated *in silico*. In particular, the miniaturisation of functional tests in water-in-oil emulsion droplets with picoliter volumes and their rapid generation and analysis (>1 kHz) allows screening of >10<sup>7</sup>-membered libraries in a day. Subsequently decoding the selected clones by short or long-read sequencing methods leads to large sequence-function datasets that may allow extrapolation from experimental directed evolution to further improved mutants beyond the observed hits. In this work, we explore experimental strategies for how to draw up 'fitness landscapes' in sequence space with uHT droplet microfluidics, review the current state of AI/ML in enzyme engineering and discuss how uHT datasets may be combined with AI/ML to make meaningful predictions and accelerate biocatalyst engineering.



## 0. Introduction

View Article Online


DOI: 10.1039/D4FD00065J

Protein engineering has made remarkable progress over the last decades, based on advances in recombinant DNA technology and site-directed mutagenesis<sup>1</sup>, directed evolution<sup>2</sup>, mechanistic and structural analysis<sup>3</sup> and computational design<sup>4</sup>. Nevertheless, the ambition of the original protein engineering, formulated as ‘*designing tailor-made enzymes for every reaction*’<sup>5</sup>, has not been fulfilled so far, still warranting Jeremy Knowles’ warning about the premature use of the term ‘engineering’ in 1987<sup>6</sup>. Two potentially crucial contributions have emerged more recently: on the one hand, development of new assay formats that make it possible to gain quantitative insight not only into *one* enzyme mutant at a time, but at a large number of them. When this comes at a low cost, by taking advantage of miniaturization - e.g. through microwells in microfluidic chambers<sup>7</sup> or in *in vitro* compartments in microfluidics<sup>8</sup> - much larger fractions of amino acid sequence space can be explored and functionally evaluated. On the other hand, machine learning offers increasingly capable algorithms suitable for interpreting such large datasets. Will it be possible to decipher complex combinatorial scenarios contained in these data and access mechanistic scenarios that would defy hypothesis-driven approaches, to enable extrapolations to inform biocatalyst engineering? Are these two approaches a natural match? Where do they synergise and how might they be combined to obtain insights on enzyme function and evolution that thus far have remained elusive?

## 1. Microdroplets as in vitro compartments generated and screened in microfluidic devices – three examples for screening workflows

Screening diversity is central to protein engineering efforts and scale is crucial to identify rare hits in the vastness of sequence space. Water-in-oil emulsions promise several orders of magnitude higher throughput compared to traditional microtiter plate screening approaches by massively reducing the volume of an experiment without use of plasticware (> 10<sup>7</sup>-fold volume reduction compared to the regular 96-well plate format with a ~200 µl volume) (**Figure 1**). A large body of work in soft matter physics has equipped us with the ability to generate water-in-oil emulsion droplets in microfluidic devices at >kHz rates that allow analysis of >10<sup>7</sup> variants per day<sup>9</sup>. Analytical interfaces exist to measure reaction progress at comparable scales, e.g. via detection by fluorescence<sup>10</sup> or absorbance<sup>11,12</sup> (or even label-free based on mass changes, albeit at lower throughput)<sup>13</sup>. When single emulsions are converted into double emulsions, commercial flow cytometers can be used for detection of fluorophores<sup>14</sup>. Further, lab-on-a-chip devices miniaturise more complex liquid handling operations and coupled assays enlarge the range of reactions that can be assayed<sup>11,15,16,17</sup>. Indeed, functional assays for all E.C. classes are already available<sup>8</sup>. The abovementioned scale and cost benefits of droplet experiments match recent advances in next generation sequencing technologies: thus large sequence-function datasets can be generated at much lower cost and with shorter lead times than conventional experimental formats (**Figure 1**). Although sequence space is notoriously vast (for a 100 amino acid protein there are 1.3\*10<sup>130</sup> possible combinations), data in which sequence and function are correlated may contribute to rough descriptions of ‘fitness landscapes’ that track and inform the navigation across more or less interesting sections of sequence space<sup>18,19</sup>.






**Figure 1: Profiles of low to ultrahigh throughput experimentation systems** (tubes, multiwell liquid handling systems, HT-MEK<sup>7</sup> and emulsion droplets<sup>8</sup>) that may be used as data generation tools for machine learning with their specific benefits and limitations.

Three examples show this technology in action, taking library screening experiments in droplets (**Figure 2**) all the way to ‘maps’ of sequence space (**Figure 3**). Each example illustrates a distinct workflow (**Figure 2**) in which large scale screening allows to infer information on fitness landscapes, generating substantial datasets that may be useful for AI/ML interpretation:


(A) *Evolution of an amine dehydrogenase (AmdH), a valuable biocatalyst for the synthesis of chiral amines.* Zurek *et al.*<sup>20</sup> screened libraries of AmdH variants generated by error-prone PCR mutagenesis. Libraries were transformed into *E. coli* for expression. Single cells were encapsulated into droplets with substrates for a coupled assay using the dye WST-1 as a turnover sensor (**Figure 2A**). Positive variants were selected based on an absorbance measurement ( $>10^5$  droplets per hour, but faster systems are now available<sup>12,21</sup>) and DNA was recovered and sequenced using UMI-linked Oxford Nanopore sequencing (UMIC-seq) to achieve high-quality.

(B) *Mutational scanning of a protein kinase involved in signaling networks.* The human protein kinase MKK1 is an example of a broad class of phosphate transfer enzymes involved in signalling networks. In order to explore how these evolve, MKK1 (which targets ERK2) was randomised with a focus on six residues in its docking domain (D-domain), which mediates interaction with the downstream kinase ERK, activating its kinase activity. Each MKK1 variant was tested for its ability to bind and phosphorylate ERK2 in a coupled assay (**Figure 2B**) exploring a scenario of neutral roaming in sequence space (i.e. a non-adaptive evolution experiment). The library was expressed (using a commercial *in vitro* transcription/translation system) in a polydisperse emulsion containing monoclonal magnetic beads. This cell free approach alleviates issues that frustrated previous *in vivo* kinase screens such as cellular background and functional redundancy, while it simultaneously benefits from the robust



expression of kinases in an *in vitro* transcription/translation system. Selections were carried out in polydisperse emulsions (not even necessitating the use of microfluidics) and the gene as well as the substrate (giving a GFP readout when a kinase target sequence was protected by successful kinase action against proteolysis) were immobilized on a bead, so that flow cytometric sorting (FACS) could be used to identify active clones. Using next-generation sequencing (NGS) of the D-domain to calculate enrichment scores, functional combinations of D-domain variants were mapped out.

(C) *Identifying promiscuous phosphotriesterases in metagenomic libraries.* A metagenomic library with 1.25 million genomic inserts of mixed environmental origins (soil, degraded plant material and cow rumen) was screened using a fluorescent assay reporting on phosphotriesterase activity (**Figure 2C**). The brightest 0,001% of droplets were sorted, sequenced using Sanger sequencing and characterised to reveal novel, uncharacterised "bridgeheads" in sequence space which is now functionally annotated in areas where homology-based classification would not have predicted phosphotriesterase activity.



**Figure 2: Ultra-high throughput screening workflows coupled to sequence data generation.** (A) Single cells can be encapsulated in droplets with substrates and lysis agent. The amine dehydrogenase reaction is coupled to WST-1 reduction forming a colorimetric readout. Active variants are sorted using AADS (absorbance-activated droplet sorting) and the output is sequenced using high-quality Nanopore sequencing (UMIC-seq). (B) Monoclonal beads carrying GFP linked via a chymotrypsin cleavage sequence are encapsulated and the kinase cascade is expressed via IVTT. A phosphorylated linker sequence is resistant to chymotrypsin cleavage. Active variants are sorted by FACS of the beads with multiple gates and the D-domain sequence and enrichment is read out via next generation sequencing (NGS). (C) Single *E. coli* cells expressing metagenomic library members are encapsulated into droplets along with a fluorogenic phosphotriester substrate. Phosphotriesterases hydrolyse the phosphotriester releasing fluorescent fluorescein. Droplets containing active variants are sorted at >1 kHz using FADS (fluorescence-activated droplet sorting) and hits are revealed by Sanger sequencing of the selected clones.



## 2. What kind of data do we generate in large scale droplet experiments?

View Article Online

DOI: 10.1039/D4FD00065J

Our objective is to reveal fitness landscapes to visualize the exploration of sequence space and ultimately steer 'walks' towards zones in which new or improved activities are more likely. Droplet experiments inform the maps by providing sequence information on individual variants correlated to a specific functional label (i.e. a qualitative or quantitative assessment of activity). While the variant sequence can be easily read out at the end of a screening workflow, functional labels can often only be obtained indirectly and require creative experimental design. Examples for such functional labels are variant identification after passing a set threshold for sorting in directed evolution or quantitative enrichment scores by deep mutational scanning<sup>22</sup>, which has recently been integrated with high throughput screening and machine learning treatment<sup>58</sup>. More generally, these labels can be categorized as binary data (e.g. selection is either successful or unsuccessful)<sup>23,24</sup> versus binned quantitative data (with granular enrichment scores)<sup>25</sup>. (These approaches are referred to as 'categorically quantitative' in **Figure 1**.)

The type of label that can be obtained from a large-scale droplet experiment is highly dependent on the chosen library size and design, the microfluidic workflow, and the choice of the sequencing strategy. NGS offers high enough sequencing depth to generate binned quantitative data (granular enrichment scores) for sequence-function mapping: reporting how often a variant occurs in the input vs. the output library. The technology used for sequencing determines the information content further. Short reads with only up to 600 bp read length (with 2x300 paired end sequencing) adequately describe mutational patterns in small proteins<sup>26</sup> or functionally defined regions of proteins<sup>25</sup> well. However, long read sequencing technologies are necessary to reveal long-range epistatic effects in larger proteins. Corresponding datasets can be obtained with PacBio or Oxford Nanopore instruments. Oxford Nanopore sequencing is cheap (<1.1¢ per sequence)<sup>20</sup> and can be carried out in any lab at low cost, while the capital expenditure for a PacBio (250,000\$ for PacBio vs <1000 for a Minion device) makes this impractical. The two technologies differ in their read quality, with PacBio giving high quality reads at single nucleotide resolution. Oxford Nanopore devices suffer from high error rates and are unable to pin-point single nucleotide mutations, but a workaround – consisting of UMI (unique molecular identifier) labelling followed by clonal amplification and consensus generation from multiple sequences (that are tagged by the same UMI)<sup>20</sup> – exists to produce high quality sequence of even single amino acid mutants. While short-read NGS can be used to generate binned quantitative data with granular enrichment scores, long-read sequencing technologies operate at lower scale (90 Gb for PacBio, 50-110 Gb for Oxford Nanopore compared to up to 3000 Gb with Illumina sequencing) and are currently limited to the generation of binary data on variant identification per round of selection in directed evolution.

Each of the three studies reviewed here (**Figure 3**) uses different experimental designs, so the sequencing strategies are correspondingly different, but all three arrive at representations of hits in sequence space that can be interpreted as fitness landscapes.

(A) *AmdH* screening (**Figure 3A**). In *AmdH* evolution long-read Nanopore sequencing (in a commercial MinION flow cell; Oxford Nanopore) was used to sequence 3000 hits with an activity higher than the threshold chosen for screening. A crucial accuracy improvement is achieved by tagging variants with unique molecular identifiers (UMIs): these are then amplified clonally, multiple nanopore sequences are generated and finally evaluated by deriving a consensus from many reads per amplified variant. In this way the sequencing accuracy was dramatically increased to > 99.99%. The improved accuracy for cost efficient long-read Nanopore sequencing is crucial for confidently resolving multiple mutations per variant and thus mapping evolutionary trajectories. The resulting dataset gives a fitness landscape shown in **Figure 3A** that illustrates the evolution of a functional protein through three generations of ultrahigh throughput screening in directed evolution, in which the 3000 best hits of 250,000 variants were sorted and sequenced.



The apparent clustering reveals intra-gene cooperativity of mutations (epistasis), for which accurate long read sequencing was necessary and provided experimental evidence for sign epistasis. Information from multiple rounds of directed evolution would constitute a dataset conditioned by the combinability of mutations. The analysis of evolutionary trajectories in this way may help to extract features for further labelling and reconstructing or extrapolating functional evolution. Such features will be identified by their acquisition and conservation through rounds of evolution and may include residues with a catalytic function (near the active site), but also enhancing solubility (on the outside of the protein), stability (e.g. residues allowing improved packing or better hydrophobic interactions in the core of a globular protein), introduction of conformational flexibility or disorder (e.g. in order to facilitate recognition of new substrates or remove steric clashes) and finally patterns of the aforementioned epistatic interactions (i.e. long range interactions between often distant residues).


(B) *Kinase screening (Figure 3B)*. The narrow focus on the well-known docking domain (D-domain) of kinases made it possible to use the short reads provided by Illumina sequencing to draw up a fitness landscape. A starting library of 500,000 mutants was generated from randomising six residues in the MKK1 docking domain (synthesised on beads by spit-and-mix assembly, with high quality and equal representation of nucleotides<sup>27</sup>). Library members were sorted into three bins according to activity.  $2.9 \times 10^4$  MKK1 variants are functional, providing a rich dataset to explore cooperativity between the different randomised positions. Enrichment analyses identified patterns of interdependence between the randomized positions, highlighting the role of cooperative hydrophobic effects and charge balance. Taken together, the patterns are displayed in a fitness landscape in which transitions from one sequence motif to another are generally possible. Many well-connected variants capable of substrate binding and phosphorylation suggest high evolvability. The extensive well-labeled sequence dataset (**Figure 3B**) carries information about implicit positive epistasis and may be further interpretable by ML in the future.

(C) *Triesterase screening (Figure 3C)*. Screening of a metagenomic library (in binary mode for overcoming a phosphotriesterase activity threshold) yielded 8 hits, the majority of which had not been recognized as phosphotriesterases before. These new enzymes will constitute bridgeheads in sequence space for further annotation, being selected for function rather than found by sequence homology. New functional motifs were recognized, e.g. an  $\alpha/\beta$  hydrolase fold, in which a catalytic triad (with a cystein nucleophile) served as a multiple turnover catalyst, despite its similarity to the target of phosphotriester as a toxin, an active site catalytic triad (containing serine) that is suicide-inhibited by the triester. Newly identified enzymes from this approach will be useful as binary activity label for ML-based functional annotation to further annotate sequences in large metagenomic databases such as MGnify<sup>28</sup>.

The three campaigns provide examples for sequence space explorations, in which the experimental design and selection criterion shapes both, the area of sequence space that is explored and the functional readout that ultimately completes a fitness landscape by adding a third, functional dimension to sequence space (as represented by two notional dimensions).

(A) The case of kinase MKK1 is producing a dataset (**Figure 3B**) focused on the small fraction of sequence space represented by docking domain mutagenesis and functionally annotated with granular enrichment scores that map a smooth fitness landscape with many overlapping functional motifs.

(B) The data on AmDH (**Figure 3A**)<sup>20</sup> covers mutations across the entire protein (being derived from an epPCR library) and thus samples a larger area of sequence space. The dataset can be interpreted as an exploration of sequence space in all directions, as long as the selection criterion of increasing AmDH activity is fulfilled (measured by a binary assay). The resulting fitness landscape is more complex and shaped by long-range epistatic effects that define founder mutations, with considerable 'ruggedness' of the fitness landscape (resulting in some mutational paths closed off due to sign epistasis), but also with evidence for positive epistasis across the protein structure (where the combined effect of two mutations can be larger than




the sum of their individual contributions). Ruggedness in the fitness landscape with fewer paths for evolution suggests that transitions are more difficult and the evolvability potentially reduced due to intrinsic response of this protein to mutations.

Open Access Article. Published on 23 April 2024. Downloaded on 8/7/2024 1:21:25 PM.

DOI: 10.1039/D4FD00065J

(C) Finally the sequence context in which new phosphotriesterases are found is much broader (**Figure 3C**)<sup>23</sup>, starting from a diverse metagenomic library (rather than a randomised single protein) and identifying peaks only in a binary screen. Additional surrounding sequences can be derived from sequence repositories, but as their function is inferred rather than tested, no inference about the shape of a fitness landscape can be made: it is simply annotated.

Interpreting large sequence collections rather than individual single mutants (e.g. a 'winner' of a selection or screening experiment) may offer additional insight. It is tempting to hope that the data can be used to reliably extrapolate from experimentally characterized variants and predict new ones with higher fitness. Cooperative epistatic effects define an evolutionary trajectory and may be inferred from information on groups of mutants (either as long-range intra-gene effects in 'founder mutants' of AmDH<sup>20</sup> or as short range effects focused on the MKK1 kinase D-domain<sup>25</sup>) and its analysis may allow predictions<sup>29</sup>. Even for metagenomic explorations<sup>23,30</sup>, functionally annotated data can be the basis prediction.



**Figure 3: Functional annotation of sequence space.** (A) Exploring productive trajectories on the fitness landscape of an amine dehydrogenase in three rounds of directed evolution<sup>20</sup>. (B) Scanning the fitness landscape of a short kinase docking domain (D-domain) with increasing thresholds for comprehensive epistasis mapping<sup>25</sup>. (C) Identifying islands of sulfatase and phosphotriesterase function in an unexplored landscape through functional metagenomics<sup>23</sup>.






### 3. The current state of AI for enzyme engineering

View Article Online

DOI: 10.1039/D4FD00065J



**Figure 4: Breakdown of key aspects of AI enzyme engineering efforts.** We distinguish between the pre-training (training on general data) and assay specific training (training on data from the targeted assay), which gives rise to three usage regimes: (i) Zero-shot = pre-training only. (ii) Assay supervised = training only. (iii) Assay aligned = pre-training + training. Note that multiple pre-training steps are possible. Further details are explained in the text.

Given the demand for green, carbon neutral biocatalytic processes that require new or improved enzymes, it is tempting for protein engineers to dream of an algorithmic black box that automatically and reliably produces instructions for enhanced activity improvements as easily as AlphaFold<sup>231</sup> comes up with a structural model. However, structure is easier to predict than activity, with the latter requiring sub-Angstrom precision in the active site and orchestrating a number of catalytic effects just in time to cross the transition state. Furthermore, the input dataset for AlphaFold2 is the well-established, rigorously quality-controlled, and systematically organized PDB which was built up in a community effort over years. In contrast, there is no such systematic framework for functional characterisation of large enzyme libraries yet. While substantial organizational effort has been put into EnzymeML<sup>32</sup>, this data exchange format is based on STRENDA, ready to receive high quality data on a few enzymes (or mutants) rather than necessarily shallower ultrahigh throughput data on fitness in larger libraries.



To discuss the interface between ultrahigh-throughput experiments and AI, we must understand the AI enzyme engineering landscape (**Table 1**). AI models differ in the extent to which they rely on rules derived from prior knowledge or autonomously identify statistical patterns in data without user input. A useful distinction can be made between *expert systems* that make decisions based on rules drawn up by a human expert (e.g. gravy hydrophobicity<sup>33</sup> or BLOSUM substitution<sup>34</sup>). In contrast, *machine learning* is an umbrella term for techniques that do not rely on such rules, but instead derive rules from data (the “learning” aspect in machine learning) (e.g. linear regression, random forest, etc.). *Deep learning* is a subclass of machine learning and loosely distinguished from general machine learning by its large count of learnable parameters: often of similar or larger order of magnitude to the available datapoints (or beyond). Many contemporary neural network approaches, such as Transformers<sup>35</sup> (the main component of modern language models<sup>36</sup>), AlphaFold2<sup>31</sup> and convolutional networks<sup>37</sup> belong to this category. The amount of data available is a first criterion in the choice of a model, with deep learning approaches being more data hungry, while general machine learning techniques can live with smaller fewer data inputs. The parameters of these models are then tuned in one or more ‘training’ steps.

The training steps determine the data used and how it informs the model's parameters. We distinguish between *pre-training steps*, which use general data such as observed sequences on UniProt or general thermostability annotations from FireProtDB<sup>38</sup>, and *assay specific training*, which uses data from the targeted assay. A *pre-training* step may proceed *self-supervised* or *supervised*: In the *self-supervised* mode only sequence or structure are available, while a functional label, e.g. an activity measurement is absent. Instead of functional labels, “pseudo-labels” unrelated to function are created by masking parts of the sequence or structure and predicting the amino acids that should occupy the masked positions. This approach is called “self” supervised, because the labels are generated from the datapoint itself, through a masking process. This pre-training mode is used e.g. for protein language models<sup>39</sup> and also for methods that take the structural environment into account<sup>40,41</sup>. By integrating this information, the model learns to pick up on common sequence or structural motifs. Alternatively, when we have access to a experimental mapping of sequence to function or a relevant proxy, a model may be pre-trained in a *supervised* way given the annotation. In contrast to general pre-training, *assay-specific training*, requires labels from the assay of interest and is therefore only possible a supervised mode.

Pre-training steps and assay-specific training can be combined. Workflows may include pre-training steps (self-supervised or supervised) along with assay-specific training. The combinations of pre-training and assay specific training give rise to three broad **usage regimes** for a model to predict a target property (or generate a sequence with a desired target property value) that is probed by a specific assay run in the lab:

(i) **zero-shot**: In this case a model is only pre-trained on general data and is used “as is” without supervised training on any assay labelled data to predict a target property. For example, a language model (such as ESM) might be trained through self-supervision (sequence masking) on all sequences observed in UniProt, and subsequently used in a “zero-shot” way by evaluating the probability that ESM assigns to a sequence containing a given mutation vs the probability of the wildtype sequence. This assumes that the target property correlates with the self-supervision task that was used during training (e.g. thermostability, because ‘natural’ motifs in UniProt must be at least marginally thermostable to be observed in living organisms). As another example, we might pre-train a linear regression model “supervised” on cDNA display proteolysis data<sup>42</sup> from general proteins, and then task the model to predict thermostability of our target protein “as is” (zero-shot).

(ii) **Assay aligned** (also referred to as ‘*transfer learning*’ or ‘task-specific fine-tuning’ in the ML community): In the assay aligned regime, a model that was previously trained (= “pre-trained model”) on general data through self-supervision or supervision is “aligned” to the assay specific data through additional supervised training on a, commonly smaller, assay specific dataset. For instance, this may be achieved by using the same model (e.g. ESM) and updating its parameters slightly based on the assay labelled sequence-to-function data (‘fine-tuning’).



As another example, one may use another model which uses representations or outputs from the pre-trained model as some of its inputs and train it on the assay labelled data ('feature extraction'). This process is illustrated for example in Hsu *et al.*<sup>43</sup> where the output of ESM is used as input to a smaller linear regression. In essence, "assay aligned" usage takes an existing pre-trained model and trains it further with assay specific data. The loose idea is that this allows "motifs" and "patterns" that can efficiently be represented by the pre-trained model to be "re-mapped" to the assay data and thereby better extract which motifs might improve or decrease the targeted property.

(iii) **Assay supervised**: In this case the given model is trained in a supervised way directly on assay data without pre-training on other data. Since the amount of available assay data is often very low, the types of models in this approach tend to be general machine learning (not deep-learning) models.

The functional coordinate defined by the assay determines the target property that is to be predicted, e.g. *thermostability*, solubility and expression, *enzyme activity* and *cumulative characteristics* (i.e. a mixed set of properties including general fitness, growth rate in the presence of antibiotic or lysate activity).

Finally *design space restrictions* can be incorporated, e.g. by explicitly restricting options based on expert knowledge, such as evolutionary or structural data at the following levels: (a) *assignment to a specific class of proteins*, e.g. an EC category or a particular fold; (b) *sequences derived from a specific protein*: starting from the WT sequence improvements in the target property are sought by mutating any position or combination of positions in the wildtype enzyme; (c) *specific regions of a starting protein* are considered preferentially – e.g. mutations in a subregion of the wildtype defined from an evolutionary conservation threshold from an MSA, expert knowledge of key positions or an enzyme structure.



**Table 1: Overview of machine learning studies for enzyme engineering.** We summarize studies in which engineered enzymes are predicted directly by the ML model and evaluated experimentally.

Enzyme		Data				AI model specification						Achievement		
Enzyme class	Reaction	Library screening	Library type	Data type	Total Data points	Data points used for ML	Model type	Training regime	Usage regime	Design space	Target property	Improvement top variant	% Success (>wt)	Reference
Oxido-reductases (EC 1)	Imine reductase (IRED)	Robotic screening (plate)	20 random singles <sup>1</sup>	conversion	11303	20*	Random forest	Supervised <sup>6</sup>	Assay supervised	Specific region <sup>4</sup>	Specific activity & conversion	specific activity: ~ wt conversion: 4.6-fold	n.a. <sup>5</sup>	44
			Mixed (singles + 1 EPCR round) <sup>1</sup>			~5'000	Random forest					Specific protein		
Mixed (singles 2 EPCR rounds) <sup>1</sup>			~8'000			Random forest & Structure-informed	Specific protein <sup>4</sup>					specific activity: 1.3-fold conversion: 7.1-fold		
	Malate dehydrogenase	Zero shot (UniProt)					Deep learning (Protein GAN)	Self-supervised	Zero-shot	Class of proteins	Specific activity	Wild-type like specific activity	22% <sup>2</sup>	45
Transferases (EC2)	Glucose Oxidase	Spectro photometer (plate)	Focused - from a previous campaign	Michaelis Menten	16 <sup>7</sup>	16 <sup>7</sup>	Machine Learning (Partial least squares)	Supervised	Assay supervised	Specific region	Michaelis Menten	$k_{cat}/K_M$ : 12.1-fold <sup>7</sup> $k_{cat}$ : 4.8-fold	One Variant	46
	Halogenase	LC-MS (plate)	Focused (3 sites)	conversion	504	504	Machine Learning (Gaussian Process)	Supervised	Assay supervised	Specific region <sup>8</sup>	Conversion	conversion: 16-fold $k_{cat}/K_M$ : 82-fold $k_{cat}$ : 93-fold	100%	47
	Hydroxylase XylM	Biosensor (plate)	Focused (5 sites)	Sensor coupled to fluorescent protein	Round 1: 126 Round 2: 126 + 50	Round 1: 126 Round 2: 126 + 50	Machine Learning & Deep Learning <sup>9</sup>	Supervised & Self-supervised	Assay supervised & Assay aligned	Specific region <sup>9</sup>	Sensor / Yield	Yield: 15-fold	Sensor: 94%	48
	Nitric oxide dioxygenase	Plate assay	Focused	Enantiomeric excess	Round 1: 124 Round 2: 155/166	Round 1: 124 Round 2: 155/166	Machine Learning <sup>3</sup>	Supervised	Assay supervised <sup>11</sup>	Specific region	Lysate activity and stereoselectivity	lysate activity: 3.2-fold; e.e.: 1.2-fold and reversed <sup>10</sup>	n.d. 360 predictions	49



	Luciferase	Bioluminescence (plate)	Focused (non-cons regions)	Bioluminescence	164	164	Machine Learning (Gaussian process & self-play reinforcement learning)	Supervised	Assay supervised	Specific region	Bioluminescence	Specific activity: 7.8-fold	72% (26/36)	50
	Methyltransferase	zero-shot (Structure-based)					Deep Learning (MutComputeX)	Self-supervised & Supervised	Zero-shot	Specific protein	Product titer	Conversion: 1.6-fold <sup>13</sup>	n.d.	51
Hydrolases (EC 3)	Beta lactamase	zero-shot (Structure-based)					Deep Learning (MutCompute)	Self-supervised	Zero-shot	Specific protein	BLA activity	Antibiotic resistance > wt, no quant measurement	30%	52
	Beta lactamase	Antibiotic resistance	error-prone PCR	Antibiotic resistance	96 and 24	96 and 24	Deep Learning (LSTM language model)	Self-supervised	Assay aligned	Specific region	Enrichment under Amp selection	Enrichment up to ~40-fold vs wildtype	2.5%	53
	TEV protease	zero-shot (deep learning-based design)					Deep Learning (Protein MPNN)	Self-supervised	Zero-shot	Specific region	Fluorogenic substrate	$k_{cat}/K_M$ : 26-fold (but mainly tied to solubility / thermostability)	3 out of 144 designs	54
	PETase	zero-shot (structure-based)					Deep Learning (MutCompute)	Self-supervised	Zero-shot	Specific protein	PET Hydrolysis Activity	Specific activity: 29-fold	80%	40
	Endonuclease (Ago Proteins – KmAgo)	zero-shot					Deep Learning (CPDiffusion)	Self-supervised (on family-focussed dataset)	Zero-shot	Specific protein <sup>1</sup> <sub>2</sub>	ssDNA cleavage assay	DNA cleavage activity: up to 8.6-fold	75%	55
	Lysozyme	zero-shot (UniProt pre-training)					Deep Learning (ProGen language model)	Self-supervised	Zero-shot	Class of proteins	Michaelis Menten kinetics	Wildtype-like activity	n.a.	56

<sup>1</sup> Training data heavily biased towards single mutations. A more sophisticated structure guided model that is less biased on single mutation data is also presented and shows similar improvements in conversion but no specific activity is reported.

<sup>2</sup> no wild type comparison available, % active variants used, all ordered (not only soluble) enzymes considered; Engineering for pH stability.

<sup>3</sup> Starting with a panel of models from scikit-learn, the top three model types were selected and used to identify the top 1,000 sequences in each predicted library.

<sup>4</sup> Presumably doubles/triples of the 20 input singles were considered.

<sup>5</sup> Possible to express 168/200 ordered double/triple mutants.

<sup>6</sup> Random forest on UniRep 1900 descriptors. Note: UniRep1900 is in principle a self-supervised trained language model, so it could be argued the training regime was supervised + self-supervised and the usage regime was assay aligned rather than assay supervised.

<sup>7</sup> Training data: (9 single mutants + 7 higher order combinations of those 9 singles from a previous DE campaign); Improvement for same pH as training data (claimed 121-fold improvement at different pH).

<sup>8</sup> The selection of these 3 sites was based on (1) docking studies with the structure and (2) previously published literature results and (3) Previous knowledge of the enzyme. This is not trivial to replicate for any enzyme.

<sup>9</sup> This study used 2 models: A more shallow machine learning based one and a deep learning based one. specific region: 5 determined via alanine scan and 50 variants were tested in each round.

<sup>10</sup> Two variant engineered (S) & (R) specific: 93% ee / 79% ee for (S/R) respectively, starting from 76% ee (S).

<sup>11</sup> Two rounds of evolution performed, while most other studies listed here perform one round.



<sup>12</sup> Based on endonuclease structure and sequence conservation data.

<sup>13</sup> direct AI prediction is a single mutant (A53M) leading to 3-fold reduced side product formation, which was then combined with other predictions (rationally/assuming additivity) to get their 17-fold reduced off product formation.

<sup>14</sup> Self-supervised: masked AA prediction in microenvironment; supervised: model selected based on correlation of zero-shot fitness with  $\Delta T_M$  of single mutants in FireProtDB.



## 4. Recent machine learning studies in enzyme engineering

The large datasets emerging from ultrahigh throughput screens will be prime candidates for machine learning analyses. Especially unbiased datasets with large coverage of design space promise to hold solutions for problems that are difficult to access with traditional hypothesis driven research. However, the current studies on enzyme engineering that involve ML are using far smaller datasets. Nevertheless, even with smaller datasets remarkable progress has been made, highlighting what the use of ML has achieved and what one may expect if more data can be fed into the algorithms.

Four groups of common workflows have been tested experimentally (see Table 1) and can be characterized by their primary variations in usage regime and design space (**Figure 3B**). We classify these as zero-shot approaches with focused (ZSF) or broad design space (ZSB) on the one hand, and, on the other hand, assay labeled regimes with focused (ALF) or broad design space (ALB). Assay labelled regimes with focused design space are usually informed by data from focused libraries targeting selected positions or regions in the protein only, in contrast to modes with a broader design space which, among others, include random mutagenesis (e.g. by error-prone PCR) across the entire protein.

### 4.1 Zero-shot regime without assay-labeled data (*yellow* sections in Table 1)

#### 4.1.1 Zero-shot with focused design space (ZSF)

Zero-shot ML only requires knowledge of the wild type sequence or structure and has been successful for identifying expressible and active variants in large design spaces, when restricted to select regions outside the active sites and highly conserved regions. Current successful zero-shot designs consistently tend to exhibit thermostability and solubility improvements. These biophysical improvements themselves can lead to activity improvements, e.g. when improved stability increases the lifetime of the biocatalyst or when improved solubility makes the biocatalyst bioavailable<sup>54,40,55</sup>, even without necessarily addressing the efficiency of the catalytic machinery itself. At the time of writing only structure-based approaches in this workflow were wet lab validated for enzymes, so we focus on two prominent structure-based examples.

**(i) MutCompute.** MutCompute is a deep learning approach (3D convolutional network) that was pre-trained in a self-supervised way based on structures in the Protein Database, by masking out amino acids in a given structure and predicting the identity of the masked amino acid based on the local context (a structural microenvironment defined by a 20 Å cube centered around the masked amino acid). MutCompute was successfully applied to the improvement of a plastic-degrading PETase by Lu et al.<sup>40</sup> in zero-shot mode, coming up with 159 variants that were experimentally tested. Combinability studies of the best mutations from this panel yielded FAST-PETase, improved by more than an order of magnitude. Enhancements are larger at higher temperatures, suggesting that temperature adaptation is the main source of catalytic improvement. Additionally, MutCompute was successfully applied with a methyltransferase<sup>51</sup> and a  $\beta$ -lactamase<sup>52</sup>.

**(ii) Protein MPNN (Figure 4A).** Protein MPNN is another deep learning model (graph neural network) originally created for sequence-redesign given a backbone structure. It is pre-trained in a self-supervised mode by 'deleting' the side-chain and amino acid information in a given structure and then re-predicting the correct sequence -- position by position (autoregressively)



-- based only on the backbone and  $C_{\beta}$  coordinates, as well as the amino acid types that it already predicted<sup>41</sup>. At usage time, a wildtype backbone structure, and optionally the amino acid types for a few fixed positions in the sequence, can be used as input and the remaining sequence is re-designed to fold into that target backbone. ProteinMPNN's pre-training has been shown to correlate with solubility and thermostability<sup>41</sup> (**Figure 4A**). The rationale is that ProteinMPNN's pre-training was based on general protein structures in which certain backbone fragments and motifs re-appear with slightly varied amino acids, such that for a given backbone fragment *plausible* (but diverse) amino acids are inferred at usage time. Since Protein MPNN has been trained on structures in the PDB, which predominantly come from crystals and therefore need to be at least modestly stable and soluble, it is thought to predict stable and soluble solutions. Existing protein structures are biased towards these properties simply by virtue of being stable enough to be observed.

A successful zero-shot application of ProteinMPNN for enzyme engineering is the work of Sumida *et al.*<sup>54</sup>, who improved the solubility and stability of TEV protease. In order not to disturb the functionally relevant constituents of the protein, evolutionarily conserved and active site residues were exempted from randomization (**Figure 5A**). 129/144 designs exhibited higher levels of soluble expression than the starting point and 64/144 designs showed some activity with a model substrate. The top three designs were further characterised on the model substrate and all showed higher catalytic efficiencies than the parent (up to 26-fold improvements) and the top hit (hyperTEV60) has 40 °C increase in melting temperature  $T_m$ . At 30 °C, hyperTEV60 retains 90% of its activity over 4h, while the parent enzyme only retains 15% activity (**Figure 5B**). These observations are consistent with the studies involving MutCompute<sup>40</sup>, namely that biophysical robustness brings about an increased ability to form product. Observing an effect on reaction kinetics (with the actual native protease substrate) would provide more direct evidence for transition state stabilization (as opposed to improving the availability of a "competent state", either by increased  $T_m$  or backbone rigidification).

The studies provide evidence that, when used in a focussed zero-shot way, models such as Mutcompute and ProteinMPNN can yield catalysts able to generate more reaction product. While biophysical characteristics are improved, the current data is less clear on improvements to the catalytic machinery. It is possible that the emphasis on stability in the pre-training data for self-supervision, which is from the general PDB and may not contain much signal on catalytic proficiency, is responsible for generating proteins mainly improved in structural integrity or solubility. If this is so, then initially unstable proteins should benefit most from these approaches and would make promising targets for ZSF machine learning approaches, although other excellent stability-enhancing algorithms already exist<sup>57</sup>). However, such an approach will miss out on potentially destabilizing mutations that may nevertheless be crucial for catalytic activation. Mutations at sites in the protein that were often deliberately excluded in these models (first shell residues, conserved residues) will not be suggested. This conservative bias in the designs may decrease the chance to find designs with improved catalysis, and may be overcome by feeding data on directed evolution trajectories (e.g. from droplet screens) into the algorithms. Higher throughput data from catalytic selections (e.g. in microdroplets) may enhance the value of models currently used in ZSF packages. It remains to be seen whether learning input from comprehensive activity screens (**Figure 3**) would give less conservative solutions, overcoming a possible learning bias from the preponderance of stable structures in the training data, and allow better extrapolation towards solutions for catalysis beyond the *conditio sine qua non* of stability.

#### 4.1.2 Zero-shot with broad design space (ZSB)

Family-based, zero-shot ML has demonstrated the ability to create new sequences that still have comparable activity to a representative reference sequence, despite exhibiting sequence similarities as low as ~60% to any known protein in the targeted family. Madani *et al.*<sup>56</sup>, for example, employ a GPT-like language model to generate lysozymes via next-token-prediction which have comparable activity to hen egg-white lysozyme. Interestingly, they found that their most active, designed sequence folds into a structure that closely mimicks that of known





proteins in that family despite the moderate 60% sequence similarity. However, beyond exploring sequence space functionally neutrally, catalytic improvements over wildtype are still elusive<sup>45 56</sup>. It is also unclear if the results carry over to protein families for which we only know few representatives, as current successful studies relied on the availability of many *bona fide* representatives of a family: for lysozyme and MDH there are >10k sequences known in each family. Further, current models in the ZSB regime only have information about family membership, but the activity of most members in a family is largely unknown. In such cases, accumulating additional functional screening data may be important for the success of ZSB to find improved variants for more exotic families.

## 4.2 Models incorporating assay-labelled data (red in Table 1)

Studies using assay-labelled data are most likely to benefit from larger amounts of screening data, especially when their design space is large. Screening datasets – the larger the better (e.g. obtained in microdroplets) – will drive the success of this area. However, compared to the entirety of possible solutions the “coverage of the problem space” is still small. Focussing on a few sites for randomization may cover a large part of the relevant space, so even when less training data are available, solutions may be found. The number of datapoints used thus far varies between 7 (InnovSar<sup>46</sup>) and 5000<sup>44</sup>. These numbers are small, even when making optimistic assumptions about the hit rates of functional proteins in sequence space. More high-quality data (covering the relevant space through a good amount of diverse datapoints that are individually reliable) might be needed, although no natural threshold for reliable predictions seems to exist (Table 1).

### 4.2.1 Models based on assay-labels in focused design space (ALF)


Assay supervised ML with small input datasets has been successful when randomization can be restricted to small regions of the protein based on previous knowledge<sup>46,47,50</sup>. **Figure 5** shows how assay-labelled data was used to engineer the activity and regioselectivity of halogenase WelO5<sup>47</sup>. The empirical dataset was generated by fully randomizing three positions identified in a docking study (yielding an 8000-membered library) (**Figure 5C**) and screening 504 variants (~6% of the theoretical diversity) in plates for product formation (**Figure 5D**). This assay-labelled data was used for supervised training of a Gaussian process model. Seven predicted variants from this model were tested and four variants showed a higher total halogenation activity than the best variant from the dataset (up to 16-fold higher than the starting point). Again, the question of what was optimized here arises: while the total turnover number (TTN) was highest for the best ML construct, Michaelis-Menten parameters were actually more improved for some of the 504 mutants from the experimental screen (93-fold improvement in  $k_{cat}$  for the best experimental candidate vs. 75-fold improvement in  $k_{cat}$  for the best ML candidate). This observation is consistent with improvements in stability for the ML-improved mutant, which correlates with the improved TTN parameter that measures long-term availability of an active enzyme, while catalytic activity (monitored in the initial rate reaction kinetics of the Michaelis-Menten treatment) was less improved.

### 4.2.2 Models based on assay-labels in broader space (ALB)

When limited or no knowledge about the target protein is available, no limits on regions and positions for randomization can be imposed and a broader space must be sampled. For example, two studies<sup>44 53</sup> incorporate single site saturation mutagenesis and error-prone PCR data in their training based on robotic screening assays and interpret these data (up to 8000 variants in case of Ma *et al.*<sup>44</sup> and 96 in case of Biswas *et al.*<sup>53</sup>, respectively) using random forest and structure-informed models. As above, improvements to better conversion are substantial (8-fold) in the best predicted mutant, while changes related to enzymatic activity are less pronounced (1.3-fold improved specific activity). Again biophysical factors seem to be easier to improve than features related to the catalytic machinery. Nevertheless, the open-



ended nature of this approach – in input (no library design necessary) as well as output (revelations not limited to targeted residues or regions) - makes ALB attractive as an innovative discovery tool. The lack of working hypothesis and vast design space, however, will make it important to generate large datasets: integration with ultrahigh throughput screening will ensure that sufficient information output is achieved describing high activity regions. Starting with a breadth of the input mutations helps to achieve coverage and efficient high throughput screening compensates for a lower hit rate in such a library, so that a sufficient number of hits is made available for ML interpretation.




**Figure 5:** Machine learning informed engineering of a TEV protease<sup>(54)</sup> and an halogenase<sup>(47)</sup>. (A) Design strategy for TEV protease engineering. Based on structural and evolutionary constraints as input, the design space was defined by fixing the amino acid identities of the active site residues and conserved residues. ProteinMPNN was used to redesign the remaining residues and generate designed sequences as output. (B) Stability assay. The best design hyperTEV60 shows improved benchtop stability compared to the native TEVd when incubated at 30°C over time. (C) Identification of engineering sites for WelO5\* halogenase. The target substrate sorafenen A was docked into WelO5\* and three positions were chosen for generating a full randomization library. (D) Activity assays for WelO5\* variants. Hits from the combinatorial library (red) and from the ML predictions (green and blue) were tested in biotransformations with cell lysate. Results are displayed as fold increase compared to the parent GAP. The best hit in the combinatorial screen was SLP and the best hit in the ML predictions was VLA.

## 5. Implications and conclusions

**More data are always better, but library design, screening technology, labeling method and sequencing approach determine interpretability**

'Smart' libraries limit the design space to a few randomized residues that can be oversampled, but rely on a reductionist model of protein function that might not reflect reality: Mutations away



from the active site or unknown hotspots are often playing unanticipated roles and proteins are typically cooperative (highlighted by the relevance of intra-gene epistasis). ML approaches will play a key role in uncovering these complex higher order phenomena that are often overlooked in traditional experiments. Instead of deep and focused, broad and unbiased coverage of sequence space may be more valuable input data for such ML endeavors.

The experimental approach used for screening determines what type of label can be attached to library members evaluated in a screening experiment. Fully quantitative datasets require cumbersome plate screening or use of high-throughput microfluidic enzyme kinetics (HT-MEK): information on multiple parameters (e.g. activity, specificity, stability) provides excellent input for ML, but the numbers of library members that can be characterized in such detail is practically limited to a few thousands. Higher throughput may aid better predictions, because the increased coverage of sequence space will give ML interpretation and extrapolation a better grounding. Experimental binning of survivors in ultra-high throughput screenings is practically straightforward (e.g. when using FACS<sup>25</sup>) and provides a ranking based on 'quantitative categories'. Experimental noise (e.g. overlap of separate bins) may compromise the data quality, but the high throughput and coverage in a microfluidic screen will mitigate this problem to some extent. Binary data, where survivors are merely measured against a threshold activity, avoids possibly experimentally elusive differences between bins and simply labels survivors based on occurrence. Binned and binary data can be obtained straightforwardly in ultrahigh throughput droplet screening, where multimillion membered libraries can be interrogated to come to grips with the combinatorial explosion of higher order interactions. The nature of the quantitative data plays a role: rankings based on lysate assays vs expression-normalised assays, long-term conversion vs initial rates, turnover of (undemanding) model substrates vs (unreactive) natural substrates etc will be different, so ML interpretations will be biased accordingly. Interpretations of these datasets need to deconvolute the combined effects of stability and activity that contribute differently to the range of quantitative descriptors outlined above. Finally, the experimental approach for sequencing determines the information content further: short reads neglect long-range interactions, but provide deeper information on limited complexity. One objective in this phase of research at the interface of ML and experiment will be to reflect on how these set-up considerations impact interpretations, even though more data must always be best.

Both approaches discussed here, ultrahigh throughput screening and machine learning, have thus far mainly been used as a powerful discovery engines of new and improved proteins. To be more than discovery tools, the current challenge is to coordinate the ability of ultrahigh throughput screening to generate large datasets with ML's potential to read and interpret complex messages, be it on catalysis, molecular recognition or protein evolution. To be useful in this respect datasets need to be large, well-labelled, diverse and of good quality. Noisy data needs to be paired with robust ML algorithms, to avoid overfitting the noise inherent in the data. Open access protocols for both ML and uHT screening should be made available, to make data compatible and interpretations comparable.

Once the screening/ML interface becomes more established it will be interesting to probe whether alternative models applied to the same dataset lead to similar molecular conclusions: if current predictions already reliably yield robust and stable proteins (e.g. with higher  $T_m$ ), will the molecular patterns that lead to higher catalytic efficiency also be revealed? The two properties are intertwined (e.g. stability enables catalytic improvement through epistatic interactions) and may be difficult to disaggregate. However, obtaining multiple datasets under different conditions – at varying temperatures or pH or with different substrates – would lead to sequence-function relationships familiar from traditional lower throughput research (e.g. pH-rate profiles, temperature denaturation curves, physical organic analysis of molecular recognition of substrates with varying reactivity or steric requirements), but apply them to many many enzyme mutants in one go. If it becomes possible to isolate and understand the molecular responses to such variations, then ML will have made ultrahigh throughput



screening a mechanistic tool, able to deal with the challenge of enormous complexity that thus far has made protein engineering more difficult than the original protein engineers envisaged.

View Article Online  
DOI: 10.1039/D4FD00065J

## Acknowledgements

The authors would like to thank Chaitanya Joshi and Charlie Harris for feedback. M.G. holds a Trinity College Benn W Levy studentship, S.M. received funding from the UKRI Centre for Doctoral Training in Application of Artificial Intelligence to the Study of Environmental Risks (EP/S022961/1). F.E.H.N. is supported by the European Union through the Marie-Curie network 'Oligomed' (956070). F.H. was an ERC Advanced Grant holder (695669).

## References

- (1) Smith, M. In vitro mutagenesis. *Annual Review of Genetics* **1985**, *19* (1), 423-462.
- (2) Arnold, F. H. Innovation by evolution: bringing new chemistry to life (Nobel Lecture). *Angew. Chem. Int. Ed* **2019**, *58* (41), 14420-14426.
- (3) Fersht, A. R. Structure and Mechanism in Protein Science. (*Freeman, New York*) **1999**.
- (4) Pan, X.; Kortemme, T. Recent advances in de novo protein design: Principles, methods, and applications. *Journal of Biological Chemistry* **2021**, *296*.
- (5) Ulmer, K. M. Protein engineering. *Science* **1983**, *219* (4585), 666-671.
- (6) Knowles, J. R. Tinkering with enzymes: what are we learning? *Science* **1987**, *236* (4806), 1252-1258.
- (7) Markin, C. J.; Mokhtari, D. A.; Sunden, F.; Appel, M. J.; Akiva, E.; Longwell, S. A.; Sabatti, C.; Herschlag, D.; Fordyce, P. M. Revealing enzyme functional architecture via high-throughput microfluidic enzyme kinetics. *Science* **2021**, *373* (6553).
- (8) Gantz, M.; Neun, S.; Medcalf, E. J.; van Vliet, L. D.; Hollfelder, F. Ultrahigh-Throughput Enzyme Engineering and Discovery in In Vitro Compartments. *Chem Rev* **2023**, *123* (9), 5571-5611.
- (9) Agresti, J. J.; Antipov, E.; Abate, A. R.; Ahn, K.; Rowat, A. C.; Baret, J.-C.; Marquez, M.; Klibanov, A. M.; Griffiths, A. D.; Weitz, D. A. Ultrahigh-throughput screening in drop-based microfluidics for directed evolution. *Proceedings of the National Academy of Sciences* **2010**, *107* (9), 4004-4009.
- (10) Baret, J.-C.; Miller, O. J.; Taly, V.; Ryckelynck, M.; El-Harrak, A.; Frenz, L.; Rick, C.; Samuels, M. L.; Hutchison, J. B.; Agresti, J. J.; et al. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. *Lab on a Chip* **2009**, *9* (13), 1850-1858.
- (11) Gielen, F.; Hours, R.; Emond, S.; Fischlechner, M.; Schell, U.; Hollfelder, F. Ultrahigh-throughput-directed enzyme evolution by absorbance-activated droplet sorting (AADS). *Proc Natl Acad Sci U S A* **2016**, *113* (47), 7383-7389.
- (12) Medcalf, E. J.; Gantz, M.; Kaminski, T. S.; Hollfelder, F. Ultra-High-Throughput Absorbance-Activated Droplet Sorting for Enzyme Screening at Kilohertz Frequencies. *Anal Chem* **2023**, *95* (10), 4597-4604.
- (13) Holland-Moritz, D. A.; Wismer, M. K.; Mann, B. F.; Farasat, I.; Devine, P.; Guetschow, E. D.; Mangion, I.; Welch, C. J.; Moore, J. C.; Sun, S.; et al. Mass Activated Droplet Sorting (MADS) Enables High-Throughput Screening of Enzymatic Reactions at Nanoliter Scale. *Angew Chem Int Ed Engl* **2020**, *59* (11), 4470-4477.
- (14) Zinchenko, A.; Devenish, S. R.; Kintses, B.; Colin, P. Y.; Fischlechner, M.; Hollfelder, F. One in a million: flow cytometric sorting of single cell-lysate assays in monodisperse picolitre double emulsion droplets for directed evolution. *Anal Chem* **2014**, *86* (5), 2526-2533.
- (15) Ladeveze, S.; Zurek, P. J.; Kaminski, T. S.; Emond, S.; Hollfelder, F. Versatile Product Detection via Coupled Assays for Ultrahigh-Throughput Screening of Carbohydrate-Active Enzymes in Microfluidic Droplets. *ACS Catal* **2023**, *13* (15), 10232-10243.
- (16) Scheele, R.; Weber, Y.; Nintzel, F.; Herger, M.; Kaminski, T. S.; Hollfelder, F. Ultrahigh throughput evolution of tryptophan synthase in droplets via an aptamer-biosensor. *ACS Catal* **2023**, in press (preprint:doi.org/10.1101/2023.1110.1111.561886).
- (17) Penner, M.; Klein, O. J.; Gantz, M.; Boss, S.; Barker, P.; Dupree, P.; Hollfelder, F. Sub-single-turnover quantification of enzyme catalysis at ultrahigh throughput via a



versatile NAD(P)H coupled assay in microdroplets. *bioRxiv* **2023**, doi.org/10.1101/2023.11.22.568356.

View Article Online

(18) Maynard Smith, J. Natural selection and the concept of a protein space. *Nature* **1970**, **225** (5232), 563-564.

(19) Svensson, E.; Calsbeek, R. *The Adaptive Landscape in Evolutionary Biology*; OUP Oxford, **2012**.

(20) Zurek, P. J.; Knyphausen, P.; Neufeld, K.; Pushpanath, A.; Hollfelder, F. UMI-linked consensus sequencing enables phylogenetic analysis of directed evolution. *Nat Commun* **2020**, **11** (1), 6023.

(21) Richter, E. S.; Link, A.; McGrath, J. S.; Sparrow, R. W.; Gantz, M.; Medcalf, E. J.; Hollfelder, F.; Franke, T. Acoustic sorting of microfluidic droplets at kHz rates using optical absorbance. *Lab Chip* **2022**, **23** (1), 195-202.

(22) Romero, P. A.; Tran, T. M.; Abate, A. R. Dissecting enzyme function with microfluidic-based deep mutational scanning. *Proc Natl Acad Sci U S A* **2015**, **112** (23), 7159-7164.

(23) Colin, P. Y.; Kintsjes, B.; Gielen, F.; Miton, C. M.; Fischer, G.; Mohamed, M. F.; Hyvonen, M.; Morgavi, D. P.; Janssen, D. B.; Hollfelder, F. Ultrahigh-throughput discovery of promiscuous enzymes by picodroplet functional metagenomics. *Nat Commun* **2015**, **6**, 10008.

(24) Kintsjes, B.; Hein, C.; Mohamed, M. F.; Fischlechner, M.; Courtois, F.; Laine, C.; Hollfelder, F. Picoliter cell lysate assays in microfluidic droplet compartments for directed enzyme evolution. *Chem Biol* **2012**, **19** (8), 1001-1009.

(25) Scheele, R. A.; Lindenburg, L. H.; Petek, M.; Schober, M.; Dalby, K. N.; Hollfelder, F. Droplet-based screening of phosphate transfer catalysis reveals how epistasis shapes MAP kinase interactions with substrates. *Nat Commun* **2022**, **13** (1), 844.

(26) Schnettler, J. D.; Wang, M.; Gantz, M.; Bunzel, A. A.; Karas, C.; Hollfelder, F.; Hecht, M. H. Selection of a Promiscuous Minimalist cAMP Phosphodiesterase from a Library of De Novo Designed Proteins. *Nature Chemistry, in press* **2024**, 10.1038/s41557-41024-01490-41554.

(27) Lindenburg, L.; Huovinen, T.; van de Wiel, K.; Herger, M.; Snaith, M. R.; Hollfelder, F. Split & mix assembly of DNA libraries for ultrahigh throughput on-bead screening of functional proteins. *Nucleic Acids Res* **2020**, **48** (11), 63.

(28) Mitchell, A. L.; Almeida, A.; Beracochea, M.; Boland, M.; Burgin, J.; Cochrane, G.; Crusoe, M. R.; Kale, V.; Potter, S. C.; Richardson, L. J.; et al. MGnify: the microbiome analysis resource in 2020. *Nucleic Acids Res* **2020**, **48** (D1), D570-D578.

(29) Miton, C. M.; Tokuriki, N. How mutational epistasis impairs predictability in protein evolution and design. *Protein Sci* **2016**, **25** (7), 1260-1272.

(30) Neun, S.; Brear, P.; Campbell, E.; Tryfona, T.; El Omari, K.; Wagner, A.; Dupree, P.; Hyvonen, M.; Hollfelder, F. Functional metagenomic screening identifies an unexpected beta-glucuronidase. *Nat Chem Biol* **2022**, **18** (10), 1096-1103.

(31) Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A. Highly accurate protein structure prediction with AlphaFold. *Nature* **2021**, **596** (7873), 583-589.

(32) Lauterbach, S.; Dienhart, H.; Range, J.; Malzacher, S.; Spring, J. D.; Rother, D.; Pinto, M. F.; Martins, P.; Lagerman, C. E.; Bommarius, A. S.; et al. EnzymeML: seamless data flow and modeling of enzymatic data. *Nat Methods* **2023**, **20** (3), 400-402.

(33) Kyte, J.; Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. *Journal of Molecular Biology* **1982**, **157** (1), 105-132.

(34) Henikoff, S.; Henikoff, J. G. Amino acid substitution matrices from protein blocks. *Proceedings of the National Academy of Sciences* **1992**, **89** (22), 10915-10919.

(35) Vaswani, A.; Shazeer, N.; Parmar, N.; Uszkoreit, J.; Jones, L.; Gomez, A. N.; Kaiser, Ł.; Polosukhin, I. Attention is all you need. *Advances in neural information processing systems* **2017**, **30**.

(36) Brown, T.; Mann, B.; Ryder, N.; Subbiah, M.; Kaplan, J. D.; Dhariwal, P.; Neelakantan, A.; Shyam, P.; Sastry, G.; Askell, A. Language models are few-shot learners. *Advances in neural information processing systems* **2020**, **33**, 1877-1901.

(37) LeCun, Y.; Bengio, Y. Convolutional networks for images, speech, and time series. In *The Handbook of Brain Theory and Neural Networks*, 1998; pp 255-258.



(38) Stourac, J.; Dubrava, J.; Musil, M.; Horackova, J.; Damborsky, J.; Mazurenko, S.; Bednar, D. FireProtDB: database of manually curated protein stability data. *Nucleic Acids Research* **2021**, *49* (D1), D319-D324. DOI: 10.1093/D4FD00065J

(39) Lin, Z.; Akin, H.; Rao, R.; Hie, B.; Zhu, Z.; Lu, W.; Smetanin, N.; Verkuil, R.; Kabeli, O.; Shmueli, Y. Evolutionary-scale prediction of atomic-level protein structure with a language model. *Science* **2023**, *379* (6637), 1123-1130.

(40) Lu, H.; Diaz, D. J.; Czarnecki, N. J.; Zhu, C.; Kim, W.; Shroff, R.; Acosta, D. J.; Alexander, B. R.; Cole, H. O.; Zhang, Y.; et al. Machine learning-aided engineering of hydrolases for PET depolymerization. *Nature* **2022**, *604* (7907), 662-667.

(41) Dauparas, J.; Anishchenko, I.; Bennett, N.; Bai, H.; Ragotte, R. J.; Milles, L. F.; Wicky, B. I.; Courbet, A.; de Haas, R. J.; Bethel, N. Robust deep learning-based protein sequence design using ProteinMPNN. *Science* **2022**, *378* (6615), 49-56.

(42) Tsuboyama, K.; Dauparas, J.; Chen, J.; Laine, E.; Mohseni Behbahani, Y.; Weinstein, J. J.; Mangan, N. M.; Ovchinnikov, S.; Rocklin, G. J. Mega-scale experimental analysis of protein folding stability in biology and design. *Nature* **2023**, *620* (7973), 434-444.

(43) Hsu, C.; Nisonoff, H.; Fannjiang, C.; Listgarten, J. Learning protein fitness models from evolutionary and assay-labeled data. *Nat Biotechnol* **2022**, *40* (7), 1114-1122.

(44) Ma, E. J.; Siirola, E.; Moore, C.; Kummer, A.; Stoeckli, M.; Faller, M.; Bouquet, C.; Eggimann, F.; Ligibel, M.; Huynh, D.; et al. Machine-Directed Evolution of an Imine Reductase for Activity and Stereoselectivity. *ACS Catalysis* **2021**, *11* (20), 12433-12445.

(45) Repecka, D.; Jauniskis, V.; Karpus, L.; Rembeza, E.; Rokaitis, I.; Zrimec, J.; Poviloniene, S.; Laurynenas, A.; Viknander, S.; Abuajwa, W.; et al. Expanding functional protein sequence spaces using generative adversarial networks. *Nature Machine Intelligence* **2021**, *3* (4), 324-333.

(46) Ostafe, R.; Fontaine, N.; Frank, D.; Ng Fuk Chong, M.; Prodanovic, R.; Pandjaitan, R.; Offmann, B.; Cadet, F.; Fischer, R. One-shot optimization of multiple enzyme parameters: Tailoring glucose oxidase for pH and electron mediators. *Biotechnol Bioeng* **2020**, *117* (1), 17-29.

(47) Buchler, J.; Malca, S. H.; Patsch, D.; Voss, M.; Turner, N. J.; Bornscheuer, U. T.; Allemann, O.; Le Chapelain, C.; Lumbroso, A.; Loiseleur, O.; et al. Algorithm-aided engineering of aliphatic halogenase WelO5\* for the asymmetric late-stage functionalization of soraphens. *Nat Commun* **2022**, *13* (1), 371.

(48) Ogawa, Y.; Saito, Y.; Yamaguchi, H.; Katsuyama, Y.; Ohnishi, Y. Engineering the Substrate Specificity of Toluene Degrading Enzyme XylM Using Biosensor XylS and Machine Learning. *ACS Synth Biol* **2023**, *12* (2), 572-582.

(49) Wu, Z.; Kan, S. J.; Lewis, R. D.; Wittmann, B. J.; Arnold, F. H. Machine learning-assisted directed protein evolution with combinatorial libraries. *Proceedings of the National Academy of Sciences* **2019**, *116* (18), 8852-8858.

(50) Wang, Y.; Tang, H.; Huang, L.; Pan, L.; Yang, L.; Yang, H.; Mu, F.; Yang, M. Self-play reinforcement learning guides protein engineering. *Nature Machine Intelligence* **2023**, *5* (8), 845-860.

(51) d'Oelsnitz, S.; Diaz, D.; Acosta, D.; Schechter, M.; Minus, M.; Howard, J.; Loy, J.; Do, H.; Alper, H. S.; Ellington, A. D. *Nature Communications* **2024**, *15*, 2084

(52) Shroff, R.; Cole, A. W.; Diaz, D. J.; Morrow, B. R.; Donnell, I.; Annapareddy, A.; Gollihar, J.; Ellington, A. D.; Thyer, R. Discovery of Novel Gain-of-Function Mutations Guided by Structure-Based Deep Learning. *ACS Synth Biol* **2020**, *9* (11), 2927-2935.

(53) Biswas, S.; Khimulya, G.; Alley, E. C.; Esvelt, K. M.; Church, G. M. Low-N protein engineering with data-efficient deep learning. *Nature Methods* **2021**, *18* (4), 389-396.

(54) Sumida, K. H.; Núñez-Franco, R.; Kalvet, I.; Pellock, S. J.; Wicky, B. I. M.; Milles, L. F.; Dauparas, J.; Wang, J.; Kipnis, Y.; Jameson, N.; et al. **2023**. DOI: 10.1101/2023.10.03.560713.

(55) Zhou, B.; Zheng, L.; Wu, B.; Yi, K.; Zhong, B.; Lio, P.; Hong, L. Conditional Protein Denoising Diffusion Generates Programmable Endonucleases, *bioRxiv*, **2023**, doi.org/10.1101/2023.08.10.552783

(56) Madani, A.; Krause, B.; Greene, E. R.; Subramanian, S.; Mohr, B. P.; Holton, J. M.; Olmos, J. L.; Xiong, C.; Sun, Z. Z.; Socher, R. Large language models generate functional protein sequences across diverse families. *Nature Biotechnology* **2023**, *41* (8), 1099-1106.



(57) Khersonsky, O.; Lipsh, R.; Avizemer, Z.; Ashani, Y.; Goldsmith, M.; Leader, H.; Dym, O.; Rogotner, S.; Trudeau, D. L.; Prilusky, J.; et al. Automated Design of Efficient and Functionally Diverse Enzyme Repertoires. *Mol Cell* **2018**, 72 (1), 178-186 View Article Online  
DOI: 10.1039/D4FD00065J

(58) Gantz, M.; Mathis, V.; Nintzel, F. E. H.; Zurek, P. J.; Knaus, T.; Patel, E.; Boros, D.; Weberling, F.-M.; Kenneth, M. R. A.; Klein, O. J.; Medcalf, E. J.; Moss, J.; Herger, M.; Kaminski, T. S.; Mutti, F. G.; Lio, P.; Hollfelder, F. Microdroplet screening rapidly profiles a biocatalyst to enable its AI-assisted engineering. *bioRxiv* **2024**, DOI: 10.1101/2024.1104.1108.588565.

